Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...
Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...
Outsourcing-pharma5h
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
The Pharma Letter5h
Second Alzheimer’s drug, donanemab, rejected for NHS use
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...
openaccessgovernment8h
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...
Armed robbery in Revesby11h
Donanemab Approved for Early Alzheimer's in Adults
Donanemab works by removing a sticky protein called beta-amyloid from the brain that is believed to cause Alzheimer's disease, and in the trials ...
National Institute for Health and Care Excellence11h
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
ITV6h
Alzheimer’s drug rejected for NHS use: What is Donanemab?
This comes as the Medicines and Healthcare Products Regulatory Agency (MHRA) said in August the drug, Donanemab, manufactured by pharmaceutical giant Eli Lilly, could be licensed for use in the UK.